InnoCan Pharma, TAU Ink Deal To Work On CBD-Based Treatment For COVID-19 | Health News

  • InnoCan will join a team led by Professor Daniel Offen, a researcher specializing in Neuroscience and Exosome technology at Tel Aviv University to collaborate on the development of a cell therapy product, based on Prof. Offen’s work in the field.
  • The two groups will collaborate on a novel, exosome-based technology that targets central nervous system (CNS) indications and COVID-19, the disease caused by the novel coronavirus.

Read full article: nocamels.com